Zeo ScientifiX, Inc. (ZEOX): Free Cash Flow
-$741.0K
Year ended 2025-10-31
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | -$741.0K | n/a | 2026-01-29, From 2024-11-01 |
| No annual figure between 2023-10-31 and 2025-10-31. | |||
| 2023-10-31 | -$2.22M | n/c | 2025-01-29, From 2022-11-01 |
| 2022-10-31 | -$3.99M | n/m | 2024-01-29, From 2021-11-01 |
| 2021-10-31 | -$3.11M | n/c | 2023-02-14, From 2020-11-01 |
| 2020-10-31 | -$1.95M | n/m | 2022-02-14, From 2019-11-01 |
| 2019-10-31 | -$598.2K | n/m | 2021-02-08, From 2018-11-01 |
| 2018-10-31 | -$516.6K | n/m | 2020-10-16, From 2017-11-01 |
| 2017-10-31 | -$926.7K | n/m | 2020-03-06, From 2016-11-01 |
| 2016-10-31 | -$574.5K | n/m | 2018-11-01, From 2015-11-01 |
| 2015-10-31 | -$448.2K | n/a | 2017-07-07, From 2014-11-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Zeo ScientifiX, Inc. (ZEOX) | 2025-10-31 | -$741.0K | n/a |
| DBV Technologies S.A. (DBVT) | 2025-12-31 | -$121.71M | n/m |
| Prime Medicine, Inc. (PRME) | 2025-12-31 | -$167.09M | n/m |
| Ocugen, Inc. (OCGN) | 2025-12-31 | -$57.15M | n/m |
| Fate Therapeutics Inc (FATE) | 2025-12-31 | -$112.04M | n/m |
| CG Oncology, Inc. (CGON) | 2025-12-31 | -$132.48M | n/m |
| CRISPR Therapeutics AG (CRSP) | 2025-12-31 | -$345.93M | n/m |
| Surrozen, Inc. (SRZN) | 2025-12-31 | -$30.37M | n/m |
| Taysha Gene Therapies, Inc. (TSHA) | 2025-12-31 | -$93.83M | n/m |
Compare ZEOX, DBVT, PRME, OCGN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗